About: http://data.cimple.eu/news-article/a1fc5f5f23ac32c6ebf12df815cb9067fae24e79d6d6c5e006d7fec1     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • -- Today, Eurofins Scientific, a world leader in Testing for Life, employing 47,000 in 800 laboratories in 50 countries published its Q1 trading statement and on this occasion announced a number of positive developments to support the worlds' fight against COVID 19: -- Eurofins has developed one of the most comprehensive testing and service offering to support healthcare practitioners and authorities around the world as well as the biopharmaceutical industry respond to the COVID-19 crisis. This includes: Several of its laboratories received approval for their laboratory-developed RT-PCR tests (LDTs) by the Food and Drug Administration (FDA) in the U.S.A. and other national authorities. Combining its own LDTs with reagents provided by its suppliers, the Group's goal is to reach a global capacity to carry out in excess of 2 million tests per month by mid-May 2020. Eurofins started to offer ELISA and CLIA-based serology testing services to detect Antibodies expressed after COVID-19 infection and capacity for these is also expected to exceed 2 million tests per month by mid-May 2020. Eurofins also launched highly specific serology testing kits to be used by state or private laboratories on most open ELISA systems and expects to reach a production capacity of over 10 million tests per month by end May 2020. Eurofins has launched a number of additional tests for example to detect the presence of SARS-CoV-2 on environmental surfaces, eg. in work or retail environment or to control Personal Protective Equipment (PPE) and medical equipment. Eurofins Genomics' six sites around the world are increasing their capacity to provide primers and probes to be incorporated in millions of SARS-CoV-2 testing kits produced by IVD companies and genome sequencing services to support research and epidemiology. The Group has also launched a large number of products and services aimed at supporting research for the development of novel vaccines and therapeutics. -- Links to all press releases published to date on the COVID-19 pandemic can be found in Eurofins Q1 2020 release You may also visit for more information. The details of methods used are available at View source version on businesswire.com: Contact For more information, please visit www.eurofins.com or contact: Investor Relations Eurofins Scientific Phone: +32 2 766 1620 E-mail: ir@eurofins.com © 2020 Business Wire, Inc. Disclaimer: This material is not an AFP editorial material, and AFP shall not bear responsibility for the accuracy of its content. In case you have any questions about the content, kindly refer to the contact person/entity mentioned in the text of the release.
schema:headline
  • Press Release from Business Wire: Eurofins Scientific
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software